US President Trump has publicly recommended that patients suffering from new coronary pneumonia take the old malaria drug “Hydroxychloroquine” (also known as “quinine”) to treat this new disease, but according to a newly published study The report pointed out that this drug is not beneficial for the treatment of new coronary pneumonia, but may expose patients to a greater risk of death.
The United States Department of Veterans Affairs (VA) published an analysis report that 97 patients who were infected with the New Coronary Pneumonia virus and received treatment in a veterans hospital were arranged to take “hydroxychloroquine” with standard medical care. %death. Another 158 patients did not take “hydroxychloroquine” and the mortality rate was 11%.
The report also showed that 113 patients were scheduled to take “hydroxychloroquine” plus the antibiotic “azithromycin” (azithromycin), the mortality rate was 22%.
However, the above analysis is not the result of a clinical experiment, nor has it been approved by other scientists for publication in an authoritative medical journal, but only uploaded to the Internet for researchers’ reference. The research subjects in the report were 368 patients who had been hospitalized in veterans hospitals across the United States due to infection with the new coronavirus and had been discharged or died on or before April 11.
The researchers found that taking “hydroxychloroquine” had no effect on whether patients needed equipment to assist in breathing. 14% of patients taking this medicine require equipment to assist in breathing, and 13% of other patients. Patients taking “hydroxychloroquine” and antibiotics at the same time, need to rely on equipment to help breathing rate is 7%.
In the past week or two, other medical reports have questioned whether “hydroxychloroquine” can effectively treat new coronary pneumonia, but larger studies and clinical trials are needed to find a definitive answer.